The delisting notice is the primary catalyst — monitor for the hearing date and any updates on the 'advanced stage' strategic transactions the company claims will restore MVPHS compliance. The business updates (new hires, product rollout, outsourcing) are incremental and unlikely to move the stock near-term. If the Panel denies an extension, delisting and a likely move to OTC would be severely negative for liquidity and valuation.
Price Chart
Executive Summary
Trinity Biotech filed a 6-K providing a business update and disclosing receipt of a Nasdaq delisting determination letter for failing to maintain the $15M minimum MVPHS. The company intends to request a hearing to appeal, which will stay any suspension. While the press release highlights commercial progress (new European commercial head, HbA1c column rollout, outsourced HIV test manufacturing, PrePsia patent expansion), the delisting risk is the dominant material event for an $8M market cap stock.
Key Facts
- Received Nasdaq delisting determination letter on August 28, 2026 for failing to regain compliance with the $15M minimum MVPHS requirement by the August 18, 2026 deadline.
- Company intends to request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension/delisting pending the hearing and any extension granted by the Panel (up to February 24, 2027).
- Company states it has initiatives and strategic transactions at advanced stages that it expects would increase MVPHS above $15M, but there is no assurance the Panel will grant an extension or that compliance will be regained.
- Announced appointment of Jordi Romero as Head of Commercial Operations Europe.
- Completed rollout of upgraded high-capacity HbA1c column system in three largest international markets.
- Completed manufacture of ~9 million TrinScreen HIV tests under new outsourced manufacturing model; commenced manufacture of Uni-Gold HIV under same model.
- Received a European patent for PrePsia early preeclampsia prediction platform, bringing total granted U.S. and European patents to nine.
Financial Impact
Delisting risk threatens Nasdaq listing for an $8M market cap company; no specific financial figures provided in the filing.
Risk Factors
- Nasdaq Panel may deny extension, leading to delisting and OTC trading.
- Strategic transactions to boost MVPHS may not close or may be dilutive.
- Quarter-to-quarter variability in Uni-Gold HIV revenues during manufacturing ramp-up.
- Forward-looking statements about transformation benefits are unquantified and aspirational.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001554855-26-001933 |
| Document: 0001554855-26-001933-index.html | 0001554855-26-001933 |
| Document: 0001554855-26-001933.txt | 0001554855-26-001933 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.30 (+26.43%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.30 (−8.81%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.30 (−24.01%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.30 (+26.09%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.30 (−31.18%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.30 (−34.69%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.30 (−37.49%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.30 (+2305.24%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.30 (+2305.24%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.30 (+1837.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers